What about Deflazacort produced by Macau Wuzhou Pharmaceutical?

Currently, Deflazacort produced by Macao Wuzhou Pharmaceutical is not yet available on the market. The main original drug available domestically and overseas is Emflaza, which was approved for marketing by a US pharmaceutical company in 2017. Emflaza is an oral corticosteroid indicated for the treatment of Duchenne muscular dystrophy in patients 2 years of age and older. Drugs can improve muscle strength and delay the progression of disability by inhibiting the inflammatory response and regulating muscle metabolism. Although deflazacort cannot cure Duchenne muscular dystrophy, it has been proven in clinical practice to significantly improve patients' quality of life and prolong the maintenance of voluntary movement function.

Overseas experience shows that Emflaza is easy to take, has stable absorption and is well tolerated. In long-term treatment of children and adolescent patients, the effects on bone density, blood sugar, and weight are relatively controllable, and the risk of side effects is low, which is why it is recommended in the management of Duchenne muscular dystrophy. In clinical use, through individualized dose adjustment and regular monitoring, the incidence of hormone-related adverse events can be reduced while ensuring the efficacy.

Although there is no production version of the drug from Macao Wuzhou on the market, if the factory develops or introduces deflazacort in the future, it will need to consider the dose equivalence, stability and clinical data support of the original drug. In terms of drug supervision and marketing approval, international and domestic standards also need to be strictly followed to ensure drug safety, effectiveness and accessibility. For patients, choosing the original drug Emflaza is still the most reliable option at present, and its clinical efficacy and long-term safety have been recognized in global multi-center studies and guidelines.

In short, although deflazacort is currently not produced by Wuzhou Pharmaceutical in Macau, the original drug Emflaza, as the core drug for the treatment of Duchenne muscular dystrophy, is still the first choice for clinical use due to its mild hormonal properties, controllable side effects and significant muscle strength improvement effect.

Reference: https://www.drugs.com/mtm/deflazacort.html